Expert Perspectives on Emerging Data Surrounding BTK Inhibitor Resistance in CLL

This is a video synopsis/summary of a News Network involving Richard Furman, MD, and Chaitra S. Ujjani, MD.

Ujjani discusses emerging evidence on resistance to second-generation Bruton tyrosine kinase (BTK) inhibitors, focusing on zanubrutinib and acalabrutinib data. She notes growing data on mutations, primarily BTK C481, but highlights the need for more profiling and consistent assays. Furman mentions a study on a serine mutation, suggesting chronic lymphocytic leukemia (CLL) clones’ inherent ability to evolve, emphasizing the importance of using different agents.

Furman expresses gratitude for Ujjani’s insights and concludes the discussion. The conversation covers sequencing considerations, treatment algorithms, and the evolving understanding of CLL clone behavior. The dialogue provides valuable perspectives on BTK inhibitor resistance, emphasizing the need for tailored treatment approaches and continuous research for more robust data.

This summary was AI-generated and reviewed by OncLive® editorial staff.